Provided by Tiger Trade Technology Pte. Ltd.

ResMed

231.36
-8.7400-3.64%
Post-market: 231.440.0800+0.03%16:18 EDT
Volume:975.60K
Turnover:226.97M
Market Cap:33.37B
PE:22.18
High:242.40
Open:239.90
Low:230.18
Close:240.10
52wk High:284.87
52wk Low:180.27
Shares:144.25M
Float Shares:143.49M
Volume Ratio:0.61
T/O Rate:0.68%
Dividend:2.40
Dividend Rate:1.04%
EPS(TTM):10.43
EPS(LYR):10.43
ROE:24.27%
ROA:14.00%
PB:5.07
PE(LYR):22.18

Loading ...

ResMed completes acquisition of Noctrix Health

Reuters
·
Jun 02

Resmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health Portfolio

THOMSON REUTERS
·
Jun 02

Movement Alert|ResMed Falls 5.08% in Regular Trading, Major Acquisition Announcement Sparks Market Concerns Over Integration Risks

Market Focus
·
May 30

ResMed Inc. Stock Falls Thursday, Underperforms Market

Dow Jones
·
May 29

ResMed Files 2025 Conflict Minerals Disclosure Under SEC Rules

TIPRANKS
·
May 27

Form SD-RMD.N

Reuters
·
May 27

How ResMed–Oura Wearable Sleep Data Partnership Could Reshape ResMed's (RMD) Clinical Ecosystem

Simply Wall St.
·
May 22

ResMed Inc. Stock Rises Tuesday, Outperforms Market

Dow Jones
·
May 20

Resmed Announces Participation in the 46th Annual William Blair Growth Stock Conference

GlobeNewswire
·
May 20

ResMed Targets Circadian Data With New Wearable Trial: What Investors Should Watch

TIPRANKS
·
May 20

ResMed partners with Oura to expand sleep health education, care pathways in US

Reuters
·
May 19

Resmed and ŌUra Partner to Expand Access to Sleep Health Education and Care

THOMSON REUTERS
·
May 19

Resmed and ŌURA Partner to Expand Access to Sleep Health Education and Care

GlobeNewswire
·
May 19

ResMed Inc. Stock Rises Monday, Outperforms Market

Dow Jones
·
May 19

Apnimed's sleep apnea pill meets main goal in late-stage study

Reuters
·
May 18

Update - Dividend/Distribution - RMD-RMD.N

Reuters
·
May 18

Understanding the "Widow's Penalty": Tax Implications After Losing a Spouse May Be Less Severe Than Anticipated

Deep News
·
May 16

Analyst Maintains Hold on ResMed as Noctrix Acquisition Offers Limited Incremental Growth Amid Competitive Risks

TIPRANKS
·
May 15

Australia R&D Changes Look Positive for CSL, Others -- Market Talk

Dow Jones
·
May 13

ResMed CEO Farrell Exercises Options and Trims Stake Under 10b5-1 Plan

TIPRANKS
·
May 12